Overview

Nonalcoholic Steatohepatitis (NASH) Market is forecasted to value over USD xx billion by 2027 end and register a CAGR of xx% from the forecast period 2020-2027.

FutureWise Market Research has illustrated a report on the Nonalcoholic Steatohepatitis (NASH) Market. The report provides an in-depth anatomy of market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.
The Nonalcoholic Steatohepatitis (NASH) Market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Nonalcoholic Steatohepatitis (NASH) Market are:    
• Boehringer Ingelheim
• Cerenis Therapeutics
• Connexios Life Sciences
• Genfit
• Islet Sciences
• Nimbus Therapeutics
• Verva Pharmaceuticals
• Viking Therapeutics
• Astazeneca Plc
• Novo Nordisk
(Note: The list of the major players will be updated with the latest market scenario and trends)

Nonalcoholic Steatohepatitis (NASH) Market Segmentation:
By Product Type
• Weight Loss Treatment
• Insulin-Sensitizing Agents
• Lipid-Lowering Drugs
• Antioxidants
• Others
By Application
• Hospital
• Clinic
• Research Institute
• Others
By Region
• North America
• Europe
• Asia-Pacific
• Rest of the world

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the market by product type, by application and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industryspecific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1 Introduction
   1.1 Objectives of the Study
   1.2 Market Definition
          1.2.1 Markets Covered
          1.2.2 Years Considered for the Study
   1.3 Currency
   1.4 Limitations
   1.5 Stakeholders

2 Research Methodology
   2.1 Research Approach
   2.2 Research Data
          2.2.1 Secondary Sources
                   2.2.1.1 Key Data from Secondary Sources
          2.2.2 Primary Sources
                   2.2.2.1 Key Data from Primary Sources
                   2.2.2.2 Breakdown of Primary Interviews
   2.3 Market Size Estimation
   2.4 Market Breakdown and Data Triangulation
   2.5 Research Assumptions

3 Executive Summary

4. Market Overview
    4.1. Introduction
           4.1.1. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
           4.3.1. Drivers
           4.3.2. Restraints
           4.3.3. Opportunities
    4.4. Global Nonalcoholic Steatohepatitis (NASH) Market Analysis and Forecast, 2020–2027
           4.4.1. Global Market Value (US$ Mn) Projections
    4.5. Porter’s Five Force Analysis
5. Global Nonalcoholic Steatohepatitis (NASH) Market Analysis and Forecast, by Product Type
    5.1. Introduction & Definition
    5.2. Key Findings / Developments
6. Global Nonalcoholic Steatohepatitis (NASH) Market Analysis and Forecast, by Application
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
7. Global Nonalcoholic Steatohepatitis (NASH) Market Analysis and Forecast, by Region
    7.1. Key Findings
    7.2. Global Nonalcoholic Steatohepatitis (NASH) Market Value Forecast, by Region
           7.2.1. North America
           7.2.2. Europe
           7.2.3. Asia Pacific
           7.2.4. Rest of the world
8 Competition Landscape
    8.1. Market Player – Competition Matrix (By Tier and Size of companies)
    8.2. Market Share Analysis by Company (2020)
    8.3. Market Footprint Analysis
           8.3.1. By Region
    8.4. Competitive Business Strategies
 
9 Company Profiles
9.1. Boehringer Ingelheim
                    9.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                    9.1.2. Product Portfolio
                    9.1.3. SWOT Analysis
                    9.1.4. Financial Overview
                    9.1.5. Strategic Overview
           9.2. CERENIS THERAPEUTICS
                    9.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                    9.2.2. Product Portfolio
                    9.2.3. SWOT Analysis
                    9.2.4. Financial Overview
                    9.2.5. Strategic Overview
           9.3. Connexios Life Sciences
                    9.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                    9.3.2. Product Portfolio
                    9.3.3. SWOT Analysis
                    9.3.4. Financial Overview
                    9.3.5. Strategic Overview
           9.4. Genfit
                    9.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                    9.4.2. Product Portfolio
                    9.4.3. SWOT Analysis
                    9.4.4. Financial Overview
                    9.4.5. Strategic Overview
           9.5. Islet Sciences
                    9.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                    9.5.2. Product Portfolio
                    9.5.3. SWOT Analysis
                    9.5.4. Financial Overview
                    9.5.5. Strategic Overview
           9.6. Nimbus Therapeutics
                    9.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                    9.6.2. Product Portfolio
                    9.6.3. SWOT Analysis
                    9.6.4. Financial Overview
                    9.6.5. Strategic Overview
           9.7. Verva Pharmaceuticals
                    9.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                    9.7.2. Product Portfolio
                    9.7.3. SWOT Analysis
                    9.7.4. Financial Overview
                    9.7.5. Strategic Overview
           9.8. Viking Therapeutics
                    9.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                    9.8.2. Product Portfolio
                    9.8.3. SWOT Analysis
                    9.8.4. Financial Overview
                    9.8.5. Strategic Overview
           9.9. Astazeneca Plc
                    9.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                    9.9.2. Product Portfolio
                    9.9.3. SWOT Analysis
                    9.9.4. Financial Overview
                    9.9.5. Strategic Overview
           9.10. Novo Nordisk
                    9.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                    9.10.2. Product Portfolio
                    9.10.3. SWOT Analysis
                    9.10.4. Financial Overview
                    9.10.5. Strategic Overview

10 Research Finding and Conclusion

11 Research Methodology

12 Research Data Source

Tables

Figures